Author

L. L. Lairson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Assay:clinical cohort / trial· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

B. S. Marro· 1 shared I. Pratumchai· 1 shared J. A. Varner· 1 shared J. Teijaro· 1 shared J. Zak· 1 shared K. L. Marquardt· 1 shared M. B. A. Oldstone· 1 shared R. Beheshti Zavareh· 1 shared

Activity by Year

2022-2022 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

B. S. Marro

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Myeloid reprogramming by JAK inhibition enhances checkpoint blockade therapy

J. Zak, I. Pratumchai, B. S. Marro, K. L. Marquardt, R. Beheshti Zavareh, L. L. Lairson, M. B. A. Oldstone, J. A. Varner, V. Bachanova, J. Teijaro

Ruxolitinib reshapes myeloid immunity to synergize with checkpoint inhibitors, enhancing anti-tumor T cell activity and improving immunotherapy outcomes.

bioRxiv · Jun 24, 2022Immunology